Evidence map›Paper›PMID 33569751›Full record

ArticleReproductive sciences (Thousand Oaks, Calif.)2021

MicroRNA-143 Sensitizes Cervical Cancer Cells to Cisplatin: a Promising Anticancer Combination Therapy.

Yalda Baghay Esfandyari, Mohammad Amin Doustvandi, Mohammad Amini, Behzad Baradaran, Sheyda Jodeiry Zaer, Nazila Mozammel, Mehdi Mohammadzadeh, Ahad Mokhtarzadeh

Abstract read
PubMed Publisher
In one paragraph

Article in Reproductive sciences (Thousand Oaks, Calif.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. HPV16Viruses · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Virus, Exosome, and MicroRNA: New Insights into Autophagy.Advances in experimental medicine and biology · 2022
    Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yalda Baghay EsfandyariDepartment of Biology, Faculty of Sciences, Urmia University, Urmia, Iran.
Mohammad Amin DoustvandiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mohammad AminiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Behzad BaradaranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Sheyda Jodeiry ZaerImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Nazila MozammelImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mehdi MohammadzadehDepartment of Biology, Faculty of Sciences, Urmia University, Urmia, Iran. m.mohamadzade@urmia.ac.ir.
Ahad MokhtarzadehImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. mokhtarzadehah@tbzmed.ac.ir.ORCID http://orcid.org/0000-0002-4515-8675
Tabriz University of Medical Sciences · IRUrmia University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin-based chemotherapy is commonly used for cervical cancer treatment. However, the development of chemoresistance is considered the main obstacle to the effectiveness of this therapeutic agent. MicroRNAs are illustrated to play a major role in the regulation of cancer cell chemosensitivity. Therefore, this study was aimed to investigate the potential therapeutic role of miRNA-143 in combination with cisplatin on cervical cancer cells. Then, CaSki cell line with low expression levels of miRNA-143 was selected for functional experiments. The cells were treated with miRNA-143 and cisplatin individually or in combination. The cell viability and apoptosis induction were evaluated by MTT, Annexin V-FITC/PI, and DAPI staining tests. Cell migration was further evaluated by wound healing assay. The effect of miRNA-143 and cisplatin combination on gene expression was quantified by real-time PCR. Furthermore, the combination therapy effect on cell cycle progression and autophagy induction was also evaluated by flow cytometry. Our results showed that miRNA-143 overexpression could increase cisplatin-induced apoptosis and increase the sensitivity of CaSki cells to low doses of this chemotherapeutic agent via modulating the expression of apoptosis-related genes including Bcl-2, Bax, and caspase-9. Besides, miRNA-143 and cisplatin were demonstrated to cooperatively increase the cell cycle arrest at the sub-G1 and G2-M phases, induce autophagy activation, and via downregulation of vimentin inhibit CaSki cell migration. Moreover, c-Myc as an important regulator of cell growth was downregulated in treatment groups compared to the control. In conclusion, regarding that miRNA-143 could sensitize cervical cancer cells to cisplatin, it may be considered a promising therapeutic strategy for the treatment of this malignancy.

Indexed as

Antineoplastic AgentsApoptosisAutophagyCell CycleCell Line, TumorCell MovementCell ProliferationCell SurvivalCisplatinHumansMicroRNAsAntineoplastic AgentsCisplatinMicroRNAsMIRN143 microRNA, humanApoptosisCell migrationCervical cancerChemotherapyCisplatinmiRNA-143

Identifiers

PMID33569751
OpenAlexW3128132897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.